CIENCIASMEDICASNEWS

New Pathways in Antithrombotic Therapy Authors: Geoffrey D. Barnes, MD, MSc; Carolyn S. P. Lam, MBBS, PhD; Christian T. Ruff, MD, MPH

https://www.medscape.org/viewarticle/new-pathways-antithrombotic-therapy-2026a1000gtd?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_261107-OUS-HONC-new-pathways-antithrombotic-therapy-2026a1000gtd-cta

Interprofessional Approach to Adverse Event Care for the Patient With High-Risk Hormone Receptor-Positive/HER2-Negative Early Breast Cancer Authors: Jonathan Malara, PharmD, BCOP; Nelli Zafman, CRNP, MSN, AOCNP

https://www.medscape.org/viewarticle/interprofessional-approach-adverse-event-care-patient-high-2026a1000gez?page=1&src=mkmcmr_driv_stan_mscpedu_261107-OUS-HONC-interprofessional-approach-adverse-event-care-patient-high-2026a1000gez-cta&uac=148436CN

Chronic Lymphocytic Leukemia: Data-Driven Updates in First-Line and R/R Disease Authors: Barbara F. Eichhorst, MD; Toby A. Eyre, MD, MBChB, DipMedEd, MRCP, FRCPath; Catherine Coombs, MD; Chan Cheah, MBBS, DMSc

https://www.medscape.org/viewarticle/chronic-lymphocytic-leukemia-data-driven-updates-first-line-2026a1000imb?page=1&src=mkmcmr_driv_stan_mscpedu_261108-OUS-HONC-chronic-lymphocytic-leukemia-data-driven-updates-first-line-2026a1000imb-cta&uac=148436CN

Income, Age Linked to Delayed Breast Cancer Care

https://www.medscape.com/viewarticle/income-age-linked-delayed-breast-cancer-care-2026a10012kp?ecd=mkm_ret_261108_mscpmrk_onc_breast-cancer_mai_etid8874665&uac=148436CN&impID=8874665

Shorter-Course Radiotherapy Is Safe Option for High-Risk Breast Cancer Dawn Attride

https://www.medscape.com/viewarticle/shorter-course-radiotherapy-safe-option-high-risk-breast-2026a10010pm?ecd=mkm_ret_261108_mscpmrk_onc_breast-cancer_mai_etid8874665&uac=148436CN&impID=8874665 Locoregional recurrence remained low over 10 years in patients with high-risk breast cancer who received shorter courses of radiotherapy after mastectomy in a phase 3 trial. Among postmastectomy patients requiring regional nodal irradiation, hypofractionated radiotherapy and conventional fractionated radiotherapy showed comparable cumulative incidence of locoregional recurrence at 5 years (9.6% vs 8.6%), the primary endpoint of the trial. There were no significant differences in survival outcomes or increases in severe late adverse effects.

PI3K Inhibitors in 2026: How a Class Built on Withdrawn Approvals Is Producing Its Strongest Breast Cancer Data Yet

https://www.medscape.com/c99/p10/pi3k-inhibitors-2026-how-class-built-withdrawn-approvals-2026a1000z8a?ecd=mkm_ret_261108_mscpmrk_onc_breast-cancer_mai_etid8874665&uac=148436CN&impID=8874665 Two PI3K inhibitors no longer exist in the United States, and two more survive only with indications stripped away. Copanlisib lost its approval in March 2024 after a required confirmatory trial failed to verify the progression-free survival benefit that had earned it accelerated approval in follicular lymphoma.FDA Umbralisib was pulled from the market entirely in June 2022 after updated trial data showed a possible increased risk of death.FDA Duvelisib's follicular lymphoma indication was voluntarily withdrawn in December 2021, and in July 2024 its label gained a new boxed warning for treatment-related mortality with an explicit instruction against first- or second-line use. Copiktra PI Idelalisib's follicular and small lymphocytic lymphoma indications were withdrawn in January 2022, leaving only a chronic lymphocytic leukemia indication on its label.